Aziridines
-
Subject Areas on Research
- An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. The CNS cancer consortium.
- An evaluation of combinations of diaziquone, etoposide and mitoxantrone in the treatment of adults with relapsed or refractory acute myeloid leukemia: results of 8722, a randomized phase II study conducted by Cancer and Leukemia Group B.
- Application of in vivo and in vitro pharmacokinetics for physiologically relevant drug exposure in a human tumor clonogenic cell assay.
- Continuous-infusion diaziquone in acute myeloid leukemia: a Southeastern Cancer Study Group trial.
- Criteria for termination of phase II chemotherapy for patients with progressive or recurrent brain tumor.
- Detecting treatment-by-centre interaction in multi-centre clinical trials.
- Evidence for a role of chloroethylaziridine in the cytotoxicity of cyclophosphamide.
- Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022.
- Intracerebral growth of a human glioma tumor line in athymic mice and treatment with procarbazine, 1,3-bis(2-chloroethyl)-1-nitrosourea, aziridinylbenzoquinone, and cis-platinum.
- Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
- Pharmacokinetics of diaziquone after three different dosage regimens.
- Phase I evaluation of diaziquone in childhood cancer. A Pediatric Oncology Group study.
- Phase II diaziquone-based chemotherapy trials in patients with anaplastic supratentorial astrocytic neoplasms.
- Phase II trial of diaziquone in anthracycline-resistant adult soft tissue and bone sarcoma patients: a Southeastern Cancer Study Group Trial.
- Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
- Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma.
- Structural requirements for high affinity ligand binding by estrogen receptors: a comparative analysis of truncated and full length estrogen receptors expressed in bacteria, yeast, and mammalian cells.
- Treatment of human glioma and medulloblastoma tumor lines in athymic mice with diaziquone and diaziquone-based drug combinations.
- Treatment of lymphohistiocytic erythrophagocytosis with VP-16 and aziridinylbenzoquinone.
- Treatment of patients with recurrent primary brain tumors with AZQ.